Close Menu

Cancer

News on cancer research & diagnostics, liquid biopsy, and cancer risk testing.

HalioDx said that Chinese oncologists will gain access to its Immunoscore assay for predicting the risk of recurrence of early-stage colon cancer.

BrightEdge was founded by the American Cancer Society to invest in for-profit companies developing novel cancer therapeutics and diagnostics.


The firm said that the new instrument, which prepares slides for cytology and aliquot samples for molecular testing, offers workflow benefits to clinical labs.

The diagnostic can now be used to identify a wider range of patients with stage III or metastatic NSCLC who may benefit from first-line treatment with Keytruda.

Decreased sales in the firm's centralized and point-of-care business and diabetes care business were partially offset by strong growth in the molecular diagnostics business.

Apr
23
Sponsored by
N-of-One

In 2016, the Association for Molecular Pathology (AMP), in partnership with the College of American Pathologists (CAP) and American College of Molecular Genetics (ACMG), launched a set of guidelines meant to set industry standards for reporting of molecular diagnostic test results in oncology, using a tier-based system and defined levels of evidence. 

Apr
24
Sponsored by
Biocrates

This webinar will provide a wide-ranging overview of the promise for metabolomics in studying human health and disease, as well as its potential for integration with other -omics disciplines.

Apr
30
Sponsored by
Lexogen

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

May
08
Sponsored by
Sysmex Inostics

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.